GE HealthCare Technologies Inc. GEHC recently announced the addition of two AI-assisted capabilities, Lung Guidance and AutoAS, to its Vscan Air handheld ultrasound system. The new tools are designed to support lung ultrasound image acquisition and the assessment of moderate-to-severe aortic stenosis (AS) at the point of care. The additions expand GE HealthCare's cardiopulmonary AI suite, helping clinicians evaluate patients with cardiac and respiratory symptoms and make more informed decisions when access to formal imaging or specialist interpretation is limited.
Per management, clinicians often have limited time and incomplete information when assessing patients with symptoms like shortness of breath, which may arise from cardiac conditions, respiratory issues or both. Lung Guidance and AutoAS are designed to bridge the gap between the initial physical assessment and the next clinical step by providing AI-enabled tools to clinicians at the point of care.
GEHC Stock Trend Following the News
GEHC stock has gained 4.2% since the announcement on Nov. 3. Year to date, the stock has returned 2.4% against the industry’s 13.4% fall. Meanwhile, the S&P 500 has risen 9.1% during the same timeframe.
The expanded AI capabilities could strengthen GE HealthCare's position in the point-of-care ultrasound market by making advanced diagnostic support more accessible. Simplified image acquisition and early identification of cardiac and pulmonary conditions may encourage wider adoption of handheld ultrasound systems. The additions could also enhance the value of its Vscan Air portfolio, support customer retention and create recurring revenue opportunities through Innovation Packages, further differentiating its ultrasound offerings.
GEHC currently has a market capitalization of $37.25 billion.
Image Source: Zacks Investment Research
More on the News
Lung Guidance provides real-time scanning assistance by directing clinicians to anatomical landmarks across the standard eight-zone lung ultrasound protocol. It detects the pleural line, A-lines, rib shadows, diaphragm and abdomen to help acquire diagnostic-quality images. AutoCapture records clips when predefined image-quality criteria are met, while Save Best Clip allows users to retain the best-quality image when those conditions are not achieved. The tool also supports B-line detection, scoring and reporting. In validation testing, non-expert users achieved a 95.2% success rate in acquiring diagnostic-quality exams, compared with 96.8% for expert users.
AutoAS provides an AI-assisted estimate of the presence or absence of moderate-to-severe aortic stenosis (AS) using standard 2D cardiac images from Vscan Air SL. It analyzes at least two compatible echocardiographic views and provides an assessment with a confidence score. Trained and validated against expert cardiologists' assessments, the tool is designed to reduce variability in missed AS compared with visual interpretation alone.
The additions build on Vscan Air's existing AI capabilities, including Caption AI, Caption Interpretation Auto EF and Auto Bladder Volume. GE HealthCare also offers AI solutions across its Venue and LOGIQ e ultrasound families. Lung Guidance and AutoAS have received FDA 510(k) clearance and CE marking. Both are available through Vscan Air Innovation Packages in the United States and select countries.
Industry Prospects Favoring the Market
According to Grand View Research, the global ultrasound AI market is estimated to reach $2.3 billion in 2026 and is projected to witness a CAGR of 28.6% through 2033.
Factors such as rising demand for early and accurate disease detection, increasing adoption of AI-assisted diagnostic imaging, growing patient imaging volumes and technological advancements in ultrasound systems are driving market growth.
Other News
GE HealthCare recently introduced Allia Celeo, a ceiling-mounted image-guided system designed to support procedural efficiency and precision imaging across cardiology and interventional radiology. Featuring an extra-wide C-arm, AI-powered precision imaging and a real-time digital twin, the system aims to optimize image quality and radiation dose while supporting diverse procedures. It also integrates predictive service technology to minimize operational disruptions.
GE HealthCare Technologies Inc. Price
GE HealthCare Technologies Inc. price | GE HealthCare Technologies Inc. Quote
GEHC’s Zacks Rank & Other Key Picks
Currently, GEHC carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are Glaukos GKOS, Intuitive Surgical ISRG and West Pharmaceutical Services WST.
Glaukos, currently flaunting a Zacks Rank #1 (Strong Buy), reported third-quarter 2026 adjusted earnings per share (EPS) of 47 cents, which surpassed the Zacks Consensus Estimate by 491.7%. Revenues of $211 million beat the Zacks Consensus Estimate by 25%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GKOS has an estimated earnings growth rate of 155.6% for 2026. The company’s earnings beat estimates in three of the trailing four quarters and missed once, the average surprise being 138.6%.
Intuitive Surgical, currently carrying a Zacks Rank #2, reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 15.5%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.
West Pharmaceutical, currently carrying a Zacks Rank #2, reported a third-quarter 2026 adjusted EPS of $2.66, which surpassed the Zacks Consensus Estimate by 22%. Revenues of $874.5 million beat the Zacks Consensus Estimate by 5.9%.
WST has an estimated long-term earnings growth rate of 17.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 18.6%.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
GE HealthCare Technologies Inc. (GEHC): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
West Pharmaceutical Services, Inc. (WST): Free Stock Analysis Report
Glaukos Corporation (GKOS): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).